



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

POLICY ON RELATED PARTY TRANSACTIONS

Preamble

The Board of Directors (the “Board”) of Spectrogen Pharmachem Limited (the “Company”), has adopted the following Policy and Procedures with regard to the Related Party Transactions as defined below. The Audit Committee shall review and may propose amendments to this Policy as may be required.

This Policy is to regulate transactions between the Company and its Related Parties based on the laws and regulations applicable on the Company.

Objective

This Policy is framed as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and intended to ensure the proper approval and reporting of transaction between the Company and its Related Parties as determined under Listing Regulations 2015, Companies Act, 2013 and rules prescribed thereunder (“Act”), and any other laws and regulations as may be applicable to the Company.

The Company is required to disclose in its Annual Financial Statements and Directors Report, certain transactions between the Company and Related Parties as well as Policy relating thereto. The Related Party Transaction Policy shall be disclosed on the website of the Company and a web link thereto shall be provided in the Annual Report.

Definitions

“Arm’s Length Transaction” means a transaction between two Related Parties that is conducted as if they were unrelated, so that there is no question of conflict of interest.

“Associate” means a Company as defined under Section 2(6) of the Companies Act, 2013 and as defined by Accounting Standard (AS) 23, “Accounting for Investments in Associates in Consolidated Financial Statements” and by Accounting Standard (AS) 18, “Related Party Disclosures”.

“Audit Committee or Committee” means the Committee of the Board formed under Section 177 of the Companies Act, 2013 and Regulation 18 of Listing Regulations 2015.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

“Board” means Board of Directors of the Company.

“Control” means control as defined in Section 2 (27) of the Act and shall have the same meaning as defined in SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

“Key Managerial Personnel” shall mean the Officers of the Company as defined in Section 2(51) of the Companies Act, 2013.

“Policy” means Related Party Transaction Policy

“Material Related Party Transaction” means a transaction with a Related Party where the transaction(s) to be entered into individually or taken together with previous transactions during a Financial Year, exceeds Ten Percent of the Annual Consolidated Turnover of the Company as per the last Audited Financial Statements of the Company.

“Related Party” as defined under Listing Regulations 2015 is as under –

An Entity shall be considered as related to the Company if:

- i. Such entity is a Related Party under section 2 (76) of the Companies Act, 2013; or
- ii. Such entity is a Related Party under the applicable accounting standards.

Section 2(76) of the Companies Act, 2013, as referred above, defines Related Party as –

1. A Director or his relative;
 2. A Key Managerial Personnel or his Relative;
 3. A Firm, in which a Director, Manager or his Relative is a Partner;
 4. A Private Company in which a Director or Manager is a Member or Director;
 5. A Public Company in which a Director or Manager is a Director and holds along with his Relatives, more than Two Percent. of its Paid-up Share Capital;
 6. Any Body Corporate whose Board of Directors, Managing Director or Manager is accustomed to act in accordance with the advice, directions or instructions of a Director or Manager; [Except advice, directions or instructions given in a professional capacity]
-



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

7. Any person on whose advice, directions or instructions a Director or Manager is accustomed to act. [Except advice, directions or instructions given in a professional capacity]
8. Any Company which is a Holding, Subsidiary or an Associate Company of such Company; or a subsidiary of a Holding Company to which it is also a Subsidiary.
9. A Director other than an Independent Director or Key Managerial Personnel of the Holding Company or his Relative with reference to a Company.

“Relative”: with reference to any person, means who is related to another, if:

- (i) They are Members of a Hindu Undivided Family;
- (ii) They are Husband or Wife or
- (iii) One Person is related to the another in the following manner, namely:
 - a. Father, includes Step-Father
 - b. Mother, includes Step-Mother
 - c. Son, includes Step-Son.
 - d. Son’s Wife
 - e. Daughter
 - f. Daughter’s Husband
 - g. Brother, includes Step-Brother
 - h. Sister, includes Step-Sister

“Related Party Transactions”

“Related Party Transaction” means a transfer of resources, services or obligations between a Listed Entity and a Related Party, regardless of whether a price is charged and a "transaction" with a Related Party shall be construed to include a single transaction or a group of transactions in a Contract.

Explanation: A transaction with a Related Party shall be construed to include single transaction or a group of transactions in a Contract.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in
Tel: 040 – 3503 5220

Website: www.spectrogen.co.in
GST: 36ABFCS1492M1ZV

As per Section 188 of the Act shall mean contracts or arrangements with Related Party with respect to:

- (a) Sale, Purchase or Supply of any Goods or Materials;
- (b) Selling or otherwise disposing of, or Buying, Property of any kind;
- (c) Leasing of Property of any kind;
- (d) Availing or rendering of any services;
- (e) Appointment of any agent for purchase or Sale of Goods, Materials, Services or Property;
- (f) Such Related Party's appointment to any Office or Place of Profit in the Company, its Subsidiary Company or Associate Company; and
- (g) Underwriting the subscription of any Securities or Derivatives thereof, of the Company.

“Collectively the Related Party Transaction shall constitute the above.”

“**Subsidiary**” means a Company as defined under Section 2(87) of the Companies Act, 2013 and as defined by Accounting Standard (AS) 23, “Accounting for Investments in Associates in Consolidated Financial Statements” and by Accounting Standard (AS) 18, “Related Party Disclosures”.

Transactions in “ordinary course of business” shall mean and include-

- Transactions that are entered in the normal and usual course of business and are identical to the business of the Company.
- Transactions that is reasonable in the context of the business of the Company.
- Transactions that are part of the Standard Industry Practice.

Identification of Related Party

Each Director and Key Managerial Personal is responsible for providing notice to the Board or Audit Committee regarding persons and entities to be considered as “Related Party” by virtue of his/her being Director/KMP in the entity or holding certain Shareholding. Such notice shall be provided to the Company at the time of appointment and also at the time of first Board Meeting in every Financial Year and whenever there is any change in the disclosures already made.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharamchem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

Identification of Potential Related Party Transactions

Each Director and Key Managerial Personnel is responsible for providing notice to the Board or Audit Committee of any potential Related Party Transaction involving him or her or his or her Relative, including any additional information about the transaction that the Board/Audit Committee may reasonably request. Board/Audit Committee will determine whether the transaction does, in fact, constitute a Related Party Transaction requiring compliance with this Policy.

Terms of the Policy

All Related Party Transactions must be reported to the Audit Committee and referred for approval by the Committee in accordance with this Policy.

All the Related Party Transactions proposed to be entered shall require prior approval of the Audit Committee including the transactions to be entered in the ordinary course of business. The Audit Committee shall accordingly recommend the Related Party Transaction for the approval of Board of Directors / Shareholders as per the terms of this Policy.

All the Related Party Transactions prescribed under Section 188 of Companies Act, 2013 and within the threshold limits prescribed under Rule 15 Sub-Rule(3) of Companies (Meetings of Board and its Powers) Second Amendment Rules, 2014, shall along with the Audit Committee Approval shall also require approval of the Board of Directors.

All the Material Related Party Transactions and Related Party Transactions, exceeding the threshold limits prescribed under Rule 15 Sub-Rule(3) of Companies (Meetings of Board and its Powers) Second Amendment Rules, 2015 shall require prior approval of the Audit Committee, Board of Directors and Shareholders of the Company by way of Special Resolution.

However, Related Party Transactions which are either not at Arm's Length or not undertaken in the ordinary course of business shall require the prior approval of the Audit Committee, Board of Directors and the Shareholders by way of Special Resolution in order to allow the Company to enter into Arrangements / Transactions / Contracts with Related Party of the Company as per the prescribed provisions of Companies Act, 2013.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

Review and Approval of Related Party Transactions

All Related Party Transactions must be reported to the Audit Committee for its prior approval in accordance with this Policy. The Committee shall review the transaction and report the same for approval of the Board and Shareholders, if required, in accordance with this Policy.

Approval of Audit Committee

All Related Party Transactions shall require prior approval of the Audit Committee either at a Meeting or by Resolutions by Circulations. Any Member of the Committee who has potential interest in any Related Party Transaction will abstain from discussion and voting on the approval of the Related Party Transaction.

The Audit Committee shall have all rights to call for information/documents in order to understand the scope of the proposed Related Party Transactions.

The Audit Committee may grant omnibus approval for the proposed Related Party Transaction subject to the following conditions:

- a. The Audit Committee shall lay down the criteria for granting omnibus approval in line with the Policy on Related Party Transactions of the Company and such approval shall be applicable in respect of transactions which are repetitive in nature;
 - b. The Audit Committee shall satisfy itself the need for such omnibus approval and that such approval is in the interest of the Company;
 - c. Such omnibus approval shall specify the following:
 - Name(s) of the Related Party;
 - Nature of the Transaction;
 - Period of Transaction;
 - Maximum amount of transaction that can be entered into;
 - The indicative base price/current contracted price and the formula for variation in the price, if any, and;
 - Such other conditions as the Audit Committee may deem fit.
-



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

d. In such cases where the need for Related Party Transaction cannot be foreseen and details as required above are not available, the Audit Committee may grant omnibus approval for such transactions subject to their value not exceeding Rupees One Crore Per Transaction;

The Audit committee shall review, at least on a quarterly basis, the details of Related Party Transactions entered into by the Company pursuant to each of the omnibus approval given; Such omnibus approvals shall be valid for a period not exceeding one year and shall require fresh approvals after the expiry of one year.

All Material Related Party Transactions will be placed for approval of the Shareholders of the Company through Special Resolution and the related parties shall abstain from voting on such Resolutions.

Approval of Board of Directors

If the Committee determines that a Related Party Transaction should be brought before the Board, or if the Board in any case elects to review any such matter or it is mandatory under any law for the Board to approve a Related Party Transaction, then the Board shall consider and approve the Related Party Transaction at a meeting and the considerations set forth above shall apply to the Board's review and approval of the matter, with such modification as may be necessary or appropriate under the circumstances.

All the Related Party Transactions prescribed under Section 188 of the Act, which are not in the ordinary course of business or not at Arm's Length Basis and all Material Related Party Transactions shall be brought before the Board and the Board shall consider and approve the Related Party Transaction at a Meeting.

Any Member of the Board who is interested or has potential interest (as mentioned under Section 184(2) of the Act), in any Related Party Transaction shall not be present at the Meeting during discussions on the subject matter of the Resolution relating to such Related Party Transaction.

Approval of Shareholders

All the Material Related Party Transactions shall require approval of the Shareholders through Special Resolution and the Related Parties shall abstain from voting on such Resolution. The Related Parties referred here shall abstain from voting irrespective of whether the Entity is a party to the particular transaction or not.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

All the Transactions, other than the Material Related Party Transaction, with the Related Parties which are not in the Ordinary Course of Business and at Arms' Length shall, subject to the limits mentioned in Rule 15 (3) of the Companies (Meeting of Board and its Power) Rules, 2014, also require the approval of the Shareholders through Special Resolution and the Related Parties shall abstain from voting on such Resolution.

The 'Related Party' referred here has to be construed with reference only to the Contract or Arrangement for which, the said Special Resolution is being passed. Thus, the term 'Related Party' in the given context, refers to only such Related Party as may be a Related Party in the context of the Contract or Arrangement for which, the said Resolution is being passed.

Transactions that, require previous approval of Shareholders of the Company, as prescribed under Rule 15(3) of the Companies (Meeting of Board and its Powers) Rules, 2014, includes the Transactions / Contracts / Arrangements as follows :

- 1) Sale, Purchase or Supply of any Goods or Materials, directly or through appointment of agent, exceeding 10% of the turnover of the Company or Rs.100 Crores, whichever is lower, as mentioned in Clause (a) and Clause (e) respectively of Sub-Section (1) of Section 188 of Companies Act, 2013;
- 2) Selling or otherwise disposing of or buying property of any kind, directly or through appointment of Agent, exceeding 10% of Networth of the Company or Rs.100 Crores, whichever is lower, as mentioned in Clause (b) and Clause (e) respectively of Sub-Section (1) of Section 188 of Companies Act, 2013;
- 3) Leasing of Property of any kind exceeding 10% of Turnover of the Company or Rs.100 Crores, whichever is lower, as mentioned in Clause (c) of Sub-Section (1) of Section 188 of the Companies Act, 2013;
- 4) Availing or rendering of any services, directly or through appointment of agent, exceeding 10% of the Turnover of the Company or Rs.50 Crores, whichever is lower, as mentioned in Clause (d) and Clause (e) respectively of Sub-Section (1) of Section 188 of Companies Act, 2013.

These limits shall however, apply for transaction or transactions to be entered into either individually or taken together with the previous transactions during a Financial Year.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

However, in case of Wholly Owned Subsidiary, the Resolution passed by the Holding Company shall be sufficient for the purpose of entering into the transactions between Wholly Owned Subsidiary and Holding Company.

Transaction not requiring approval of Audit Committee, Board of Directors or Shareholders

Notwithstanding the foregoing, the following Related Party Transactions shall not require approval of Audit Committee, Board of Directors or Shareholders:

- i. Any transaction that involves the providing of compensation to a Director or Key Managerial Personnel in connection with his or her duties to the Company or any of its Subsidiaries or Associates, including the reimbursement of reasonable business and travel expenses incurred in the ordinary course of business.
- ii. Any transaction in which the Related Party's interest arises solely from ownership of securities issued by the Company and where all holders of such securities receive the same benefits pro rata as the Related Party.

Transaction not requiring approval of Board of Directors or Shareholders

Pursuant to clarification provided in Circular No. 30/2014 dated July 17, 2014 of Ministry of Corporate Affairs, Contracts entered into by Companies, after making necessary compliances under Section 297 of the Companies Act, 1956, which already came into effect before the commencement of Section 188 of the Companies Act, 2013, will not require fresh approval under the said Section 188 till the expiry of the original term of such Contracts.

Thus, if any modification in such Contract is made on or after April 1, 2014, the requirements under Section 188 will have to be complied with.

Criteria for approval of Related Party Transactions

To review a Related Party Transaction, the Board of Directors, or the Audit Committee, will be provided with all relevant material information of the Related Party Transaction, including the terms of the transaction, the business purpose of the transaction, the benefits to the Company and to the Related Party, and any other relevant matters. i. the name of the Related Party and nature of relationship; ii. the nature, duration of the contract and particulars of the Contract or Arrangement;



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

- Material Terms of the Contract or Arrangement including the value, if any;
- Any Advance Paid or Received for the Contract or Arrangement, if any;
- The manner of determining the Pricing and other commercial terms, both included as part of Contract and not considered as part of the Contract;
- Whether all factors relevant to the Contract have been considered, if not, the details of factors not considered with the rationale for not considering those factors;
- The Authority approving the Transaction; and
- Any other information relevant or important for the Committee to take a decision on the proposed transaction.

The information provided shall specifically cover the following:

In determining whether to approve a Related Party Transaction, the Board of Directors / Audit Committee shall consider the following factors, amongst others, to the extent relevant to the Related Party Transaction:

- i. Whether the Transaction is in the ordinary course of business of the Company.
 - ii. Whether the terms of the Related Party Transaction are fair and on Arm's Length Basis to the Company and would apply on the same basis if the transaction did not involve a Related Party;
 - iii. Whether there are any undue compelling business reasons for the Company to enter into the Related Party Transaction and the nature of alternative transactions, if any;
 - iv. Whether the Related Party Transaction would affect the Independence of the Directors / KMP;
 - v. Whether the proposed transaction includes any potential reputational risk issues that may arise as a result of or in connection with the proposed transaction;
 - vi. Where the ratification of the Related Party Transaction is allowed by law and is sought from the Committee, the reason for not obtaining the prior approval of the Committee and the relevance of business urgency and whether subsequent ratification would be detrimental to the Company; and
-



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

vii. Whether the Related Party Transaction would present an improper conflict of interest for any Director or Key Managerial Personnel of the Company, taking into account the size of the transaction, the overall financial position of the Director, Executive Officer or other Related Party, the direct or indirect nature of the Director's, Key Managerial Personnel's or other Related Party's interest in the transaction and the ongoing nature of any proposed relationship and any other factors, the Board of Directors / Audit Committee deems relevant.

Disclosures

Every Director of a Company who is in any way, whether directly or indirectly, concerned or interested in a Contract or Arrangement or proposed Contract or Arrangement entered into or to be entered into –

(a) With a Body Corporate in which such Director or such Director in association with any other Director, holds more than Two Percent Shareholding of that Body Corporate, or is a Promoter, Manager, Chief Executive Officer of that Body Corporate; or

(b) With a Firm or other Entity in which, such Director is a Partner, Owner, or Member, as the case may be, shall disclose the nature of his concern or interest at the Meeting of the Board of Directors in which the Contract or Arrangement is discussed and shall not participate in such Meeting.

Provided that where any Director who is not so concerned or interested at the time of entering into such Contract or Arrangement, he shall, if he becomes concerned or interested after the Contract or Arrangement is entered into, disclose his concern or interest forthwith when he becomes concerned or interested or at the First Meeting of the Board of Directors held after he becomes so concerned or interested.

All Director's / KMP's are required to disclose the Entities in which they or their Relatives are or deemed to be interested, in the prescribed form.

Each Director and KMP of the Company shall promptly notify the Company Secretary of the Company of any Material Transaction or Relationship that could reasonably be expected to give rise to any conflict of interest.

The Company shall maintain Register pertaining to Related Party Transactions in the prescribed form.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

The Related Party Transaction entered into with the Related Party shall be disclosed in the Annual Report as per the disclosure requirement of the Act.

The Company shall disclose the Policy on dealing with Related Party Transactions on its website and a web link thereto shall be provided in the Annual Report.

Details of all the Material Transactions with the Related Parties shall be disclosed, on quarterly basis, before the Audit Committee.

Ratification of Related Party Transactions

Any Related Party Transaction entered into without obtaining the prior approval of the Audit Committee / Board of Directors / Shareholders (respective authority/ies) may be ratified, subject to the applicable provisions of the Companies Act, 2013 and the Listing Regulations 2015, if post-review of the said transaction, the Appropriate Authority is satisfied, that the said Related Party Transaction is not detrimental to the interest of the Company, however, the Appropriate Authority may also ratify such transaction or contracts, with or without the modification(s).

Where any Contract or Arrangement is entered into, without obtaining the consent of the Audit Committee, Board or approval by a Special Resolution in the General Meeting and if it is not ratified by the Board or, as the case may be, by the Shareholders at a Meeting within three months from the date on which such Contract or Arrangement was entered into, such Contract or Arrangement shall be voidable at the option of the Board.

If the Appropriate Authority decides, not to approve a particular transaction, it may require the Related Party to reimburse the benefits which might have accrued to it and / or indemnify the Company with regards to the subject Related Party Transaction which is not approved by the Appropriate Authority.

However, the Related Party Transaction which are entered into without the approval of the Appropriate Authority and subsequently not ratified, the applicable provisions of the Companies Act, 2013 and Listing Regulations, 2015, shall apply.



SPECTROGEN PHARMACHEM LIMITED
(Formerly, Spectrogen Pharmachem Private Limited)
CIN: U24299TG2020PLC147109

E-mail: info@spectrogen.co.in

Tel: 040 – 3503 5220

Website: www.spectrogen.co.in

GST: 36ABFCS1492M1ZV

Amendments

The Board of Directors on its own and / or as per the recommendations of Audit Committee can amend this Policy, as and when deemed fit. Any or all provisions of this Policy would be subject to revision / amendment in accordance with the Rules, Regulations, Notifications etc. on the subject as may be issued by relevant statutory authorities, from time to time.

In case of any amendment(s), clarification(s), circular(s) etc. issued by the relevant authorities, not being consistent with the provisions laid down under this Policy, then such amendment(s), clarification(s), circular(s) etc. shall prevail upon the provisions hereunder and this Policy shall stand amended accordingly from the effective date as laid down under such amendment(s), clarification(s), circular(s) etc.

This Policy will be communicated to all operational employees and other concerned persons of the Company and shall be placed on the website of the Company.
